• Basic Protein Native PAGE Kit (K4142)

  2026-08-08

  The Basic Protein Native PAGE Gel Preparation and Electrophoresis Kit supports native protein gel electrophoresis for proteins with pI ≤ 7.0. Its acidic-protein workflow uses non-denaturing conditions, gel sieving, and charge-dependent mobility to help preserve structure and biological activity during separation.

• Phosphotungstic Acid Negative Stain Solution: EM

  2026-08-07

  Turn purified spikes, virions, bacteria, and macromolecular assemblies into high-contrast electron microscopy targets with a ready-to-use 2% negative stain. This workflow connects morphology checks to coronavirus entry research while clearly separating structural evidence from glycan-binding and antiviral conclusions.

• Transdermal PTEN mRNA Delivery with HA-LNPs for Melanoma The

  2026-08-07

  This study introduces a hyaluronate-conjugated lipid nanoparticle (HA-LNP) system for non-invasive, transdermal delivery of PTEN mRNA, targeting immune-evasive melanoma. By replacing PEG with HA-DMG, the platform achieves efficient tumor suppressor gene expression, immune activation, and tumor inhibition, demonstrating a promising advance in localized mRNA-based cancer immunotherapy.

• NADH in Metabolic and Mitochondrial Research: Applied Workfl

  2026-08-06

  Leverage reduced nicotinamide adenine dinucleotide (NADH) for robust interrogation of cellular energy metabolism, mitochondrial function, and redox-driven disease models. This article bridges cutting-edge protocol design, troubleshooting, and comparative insight to maximize reproducibility and innovation in NADH-based research.

• Ibotenic acid (SKU B6246): Reliable NMDA Receptor Agonist fo

  2026-08-06

  This scenario-driven guide explores how Ibotenic acid (SKU B6246) from APExBIO addresses real laboratory challenges in neurodegeneration research. Drawing on recent in vivo evidence, the article demonstrates best practices, data interpretation strategies, and product selection tips that drive reproducibility and workflow efficiency for cell viability, cytotoxicity, and neuronal injury assays.

• Risedronate Sodium: Expanding Horizons in Bone and Cancer Re

  2026-08-05

  Explore the advanced roles of Risedronate Sodium as a FPP synthase inhibitor in both bone metabolism and cancer research. This article delivers a deep, evidence-based analysis of its molecular action, translational applications, and protocol guidance for next-generation assays.

• AO/PI Staining Solution: Redefining Cell Viability for Trans

  2026-08-05

  Explore how AO/PI Staining Solution, a dual fluorescent DNA dye reagent from APExBIO, is transforming the rigor and reproducibility of live/dead cell discrimination in translational research. This thought-leadership piece bridges mechanistic clarity, workflow strategy, and clinical relevance, with actionable guidance for optimizing fluorescence-based viability assays—especially in disease models such as diabetic nephropathy, where precise cell quantification underpins impactful discovery.

• Canagliflozin as an SGLT2 Inhibitor: Advanced Diabetes Resea

  2026-08-04

  Canagliflozin is redefining diabetes and kidney research by combining potent SGLT2 inhibition with mitochondrial remodeling capabilities. Discover optimized workflows, troubleshooting tips, and actionable protocol parameters that leverage this dual-action compound for maximum assay sensitivity and translational relevance.

• Diclofenac as a Non-Selective COX Inhibitor in Organoid Rese

  2026-08-04

  Diclofenac’s high purity and solubility make it an ideal tool for advanced cyclooxygenase inhibition assays in complex human iPSC-derived intestinal organoid models. This article details experimental setup, protocol parameters, troubleshooting, and the translation of new pharmacokinetic approaches for inflammation and pain signaling pathway studies.

• Precision Control in Genome Editing with EZ Cap™ Cas9 mRNA (

  2026-08-03

  Explore how EZ Cap™ Cas9 mRNA (m1Ψ) enables unprecedented precision and temporal control in CRISPR-Cas9 genome editing. This article reveals new insights into mRNA nuclear export, specificity, and the practical implications for advanced gene editing workflows.

• Optimizing Genome Editing with EZ Cap™ Cas9 mRNA (m1Ψ) R1014

  2026-08-03

  This article addresses common challenges in CRISPR-Cas9 genome editing, focusing on the scientific and workflow benefits of EZ Cap™ Cas9 mRNA (m1Ψ) (SKU R1014). Through scenario-driven Q&A, it demonstrates how mRNA with Cap1 structure and m1Ψ modification improves editing precision, immune evasion, and reproducibility, supporting reliable outcomes for biomedical researchers.

• DMXAA (Vadimezan): Workflow Advances in Tumor Vasculature Di

  2026-08-02

  DMXAA (Vadimezan) sets a benchmark for targeted vascular disruption and apoptosis induction in cancer biology research. This guide delivers actionable workflows, troubleshooting insights, and integrates the latest endothelial STING-JAK1 findings to optimize your anti-angiogenic and immunomodulatory assays.

• Ouabain: Unveiling Ion Transport Dynamics Beyond Standard As

  2026-08-01

  Explore the scientific depth of Ouabain as a selective Na+/K+-ATPase inhibitor, with a unique focus on dissecting cellular ion transport, signaling, and cardiac physiology. This article delivers method-level insight and comparative guidance for advanced research.

• SN-38 Inhibits FUBP1-FUSE Binding: Mechanistic Insights in C

  2026-07-31

  This study uncovers that camptothecin and its analog SN-38, beyond inhibiting DNA topoisomerase I, also disrupt the interaction of the transcriptional regulator FUBP1 with its DNA target FUSE. These dual mechanisms may help explain the efficacy of SN-38 in models of advanced colon and liver cancer, offering new perspectives for targeted cancer research.

• HDAC Inhibition Reverses EBV-Induced Plasticity in NPC Cells

  2026-07-31

  This study elucidates how HDAC inhibition can reverse Epstein-Barr virus (EBV)-induced dedifferentiation in nasopharyngeal carcinoma (NPC) by targeting cancer cell plasticity at the epigenetic level. The findings provide both mechanistic insight and translational evidence for differentiation therapy in solid tumors, expanding the potential for epigenetic intervention beyond hematological malignancies.

7963 records 4/531 page Previous Next 12345 下5页 Last page